[go: up one dir, main page]

WO2018056824A8 - Manipulation of immune activity by modulation of expression - stub1 - Google Patents

Manipulation of immune activity by modulation of expression - stub1 Download PDF

Info

Publication number
WO2018056824A8
WO2018056824A8 PCT/NL2017/050639 NL2017050639W WO2018056824A8 WO 2018056824 A8 WO2018056824 A8 WO 2018056824A8 NL 2017050639 W NL2017050639 W NL 2017050639W WO 2018056824 A8 WO2018056824 A8 WO 2018056824A8
Authority
WO
WIPO (PCT)
Prior art keywords
stub1
expression
immune activity
manipulation
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2017/050639
Other languages
French (fr)
Other versions
WO2018056824A1 (en
Inventor
Antonius Nicolaas Maria Schumacher
Thijn Reinout BRUMMELKAMP
Chong SUN
Lucas Tilmann JAE
Riccardo Ernesto MEZZADRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Netherlands Cancer Institute
Original Assignee
Netherlands Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Cancer Institute filed Critical Netherlands Cancer Institute
Publication of WO2018056824A1 publication Critical patent/WO2018056824A1/en
Publication of WO2018056824A8 publication Critical patent/WO2018056824A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the field of immunity, immune activity and more particularly to the field of "immune check points" including the PD-1/PD-L1 axis, and conditions or diseases involving PD-1/PD-L1 axis signaling. Provided are modulators of immune activity, which modulators influence the activity and/or expression of STUB1.
PCT/NL2017/050639 2016-09-23 2017-09-25 Manipulation of immune activity by modulation of expression - stub1 Ceased WO2018056824A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
NL2017523 2016-09-23
NL2017523 2016-09-23
NL2019271 2017-07-18
NL2019271 2017-07-18
NL2019281 2017-07-19
NL2019281 2017-07-19

Publications (2)

Publication Number Publication Date
WO2018056824A1 WO2018056824A1 (en) 2018-03-29
WO2018056824A8 true WO2018056824A8 (en) 2018-06-28

Family

ID=60138904

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/NL2017/050639 Ceased WO2018056824A1 (en) 2016-09-23 2017-09-25 Manipulation of immune activity by modulation of expression - stub1
PCT/NL2017/050640 Ceased WO2018056825A1 (en) 2016-09-23 2017-09-25 Manipulation of immune activity by modulation of expression

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/NL2017/050640 Ceased WO2018056825A1 (en) 2016-09-23 2017-09-25 Manipulation of immune activity by modulation of expression

Country Status (2)

Country Link
EP (1) EP3516390A1 (en)
WO (2) WO2018056824A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
GB201805963D0 (en) * 2018-04-11 2018-05-23 Avacta Life Sciences Ltd PD-L1 Binding Affirmers and Uses Related Thereto
WO2019237388A1 (en) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 Grna sequence for knocking out human btdc gene and application thereof
CN114380907B (en) * 2020-10-16 2024-06-18 中国科学院上海药物研究所 Nanometer antibody targeting CMTM6, and preparation method and application thereof
CN112195224A (en) * 2020-10-23 2021-01-08 漯河医学高等专科学校 Application of gene combination detection reagents in immunotherapy of lung cancer patients
CN116832177A (en) * 2022-03-25 2023-10-03 中国科学院上海药物研究所 Preparation and anti-tumor application of gene therapy vectors that interfere with the expression of chemokine-like factor superfamily member 6 (CMTM6)
CN116942829A (en) * 2023-07-31 2023-10-27 北京大学第三医院（北京大学第三临床医学院） Application of membrane protein CMTM4 as drug target for treating inflammatory bowel disease and marker for monitoring UC disease progress

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20040029114A1 (en) * 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20070134261A1 (en) * 2001-12-03 2007-06-14 Hancock Robert E Effectors of innate immunity
US20060099645A1 (en) 2002-09-06 2006-05-11 Mount Sinai Hospital Methods and reagents for assaying molecular interactions
US7659077B2 (en) * 2003-03-17 2010-02-09 Riikka Lund Methods utilizing target genes related to immune-mediated diseases
JP5150909B2 (en) * 2005-07-27 2013-02-27 オンコセラピー・サイエンス株式会社 How to diagnose esophageal cancer
US20090022731A1 (en) * 2006-08-25 2009-01-22 Wyeth Arthritis-associated B cell gene expression
CN101148472A (en) * 2006-09-13 2008-03-26 北京大学 New tumor suppressor gene or protein and its application
CN101161283B (en) * 2006-10-10 2012-07-11 北京大学 New applications of CMTM1-v17 and its antagonists
CN101550185B (en) * 2008-04-03 2013-10-30 北京大学 Tumor-related gene or protein and application thereof
WO2010037124A1 (en) * 2008-09-29 2010-04-01 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
SG173105A1 (en) 2009-02-16 2011-09-29 Epict Technologies Corp Template-independent ligation of single-stranded dna
US20120252028A1 (en) * 2009-08-14 2012-10-04 Michael Shtulman Target genes for cancer therapy
EP2591797A4 (en) * 2010-07-09 2014-01-15 Inst Pasteur Of Shanghai Cas FACTOR FOR REGULATING FOXP3 AND REGULATORY T CELLS AND USE THEREOF
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
RU2015140941A (en) * 2013-02-27 2017-03-30 Те Брод Инститьют, Инк. EXPRESSION OF GENES AFFECTING THE T-CELL BALANCE, THEIR COMPOSITIONS AND METHODS OF APPLICATION
MX369709B (en) 2013-03-15 2019-11-19 Univ Pennsylvania IMPROVED VACCINATION AGAINST TYROSINASE.
CN104225575B (en) * 2013-06-07 2019-08-02 北京大学人民医院 A tumor suppressor gene or protein and its application
CN105879053A (en) * 2014-09-26 2016-08-24 北京大学 Use of CMTM1-V5 gene and its encoded protein

Also Published As

Publication number Publication date
EP3516390A1 (en) 2019-07-31
WO2018056825A1 (en) 2018-03-29
WO2018056824A1 (en) 2018-03-29
WO2018056825A8 (en) 2019-05-31

Similar Documents

Publication Publication Date Title
WO2018056824A8 (en) Manipulation of immune activity by modulation of expression - stub1
CL2019000325A1 (en) Pharmaceutical composition comprising a compound derived from substituted polycyclic pyridone or its salt, which has cap-dependent endonuclease inhibitory activity; crystal; and pharmaceutical composition comprising said crystal.
WO2015191951A3 (en) Modulation of complement activity
WO2018124766A3 (en) Chimeric antigen receptor and natural killer cells expressing same
MX2018013495A (en) INTEGRATED STRESS TRAIL MODULATORS.
WO2016172658A3 (en) Microbiome regulators and related uses thereof
MX2018011139A (en) Acrylic acid, and methods of producing thereof.
UY37230A (en) INTEGRATED STRESS ROAD MODULATORS
UY37231A (en) INTEGRATED STRESS ROAD MODULATORS
MX2020012132A (en) AZAPIRIDONE COMPOUNDS AND USES THEREOF.
AU2017260374A1 (en) Modulators of the integrated stress pathway
MX2023004969A (en) METHODS FOR TREATING AND PREVENTING<i> C. DIFFICILE </i>INFECTION.
HK1255034A1 (en) Somatostatin modulators and uses thereof
PH12016500492B1 (en) Pyridazinone compounds and uses thereof
WO2017066712A3 (en) Modulators of telomere disease
MX383931B (en) AZA-PYRIDONE COMPOUNDS AND THEIR USES.
BR112018011504A2 (en) thrombin microcapsules
HK1255074A1 (en) Somatostatin modulators and uses thereof
WO2016138538A3 (en) Therapeutic use of integrin-binding antibodies
WO2017066796A3 (en) Modulators of telomere disease
HK1252343A1 (en) Compositions and methods for the treatment of viral infection
MX2017002768A (en) Antiviral agents and uses thereof.
WO2016109361A3 (en) 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
WO2015144977A8 (en) Trpa1 modulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17787047

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17787047

Country of ref document: EP

Kind code of ref document: A1